TAS-102 for Colorectal Cancer with Minimal Residual Disease
This study is looking at how well the drug TAS-102 works in people with colorectal cancer who have completed their initial treatments. Doctors want to see if TAS-102 can clear up any remaining cancer cells, which are detected by a blood test called circulating tumor DNA (ctDNA). You might be able to join if you've had surgery for colorectal cancer (stages II, III, or IV) and completed at least three months of chemotherapy. The main goal is to see how many participants have no ctDNA detected after six months of taking TAS-102. The study plans to enroll 25 people, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 25 participants.
- What's involved
- Participants will receive TAS-102 orally (by mouth) for six months. ctDNA levels will be measured at three and six months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at up to 6 months, and secondary endpoints include disease-free survival and overall survival, suggesting follow-up beyond the treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Alisha Bent, MD · STUDY_CHAIR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.up to 6 months